This is a StreetInsider.com Premium Only Page

Amicus Therapeutics (FOLD) – StreetInsider.com Reports

Apr 12, 2024 04:54 AM Amicus Therapeutics (FOLD) PT Lowered to $14 at BofA Securities

Mar 18, 2024 08:37 AM Amicus Therapeutics (FOLD) PT Lowered to $19 at JPMorgan

Feb 28, 2024 07:12 AM Amicus Therapeutics (FOLD) Tops Q4 EPS by 7c, provides guidance

Jan 8, 2024 05:24 AM Amicus Therapeutics (FOLD) Reports Prelim FY23 Revenue, Provides 2024 Outlook

Dec 19, 2023 03:12 AM Morgan Stanley Upgrades Amicus Therapeutics (FOLD) to Overweight

Nov 8, 2023 05:28 PM Amicus Therapeutics (FOLD) Announces 2.47M Share Offering by Selling Stockholders

Nov 8, 2023 04:32 PM Amicus Therapeutics (FOLD) PT Raised to $15 at Morgan Stanley

Nov 8, 2023 07:05 AM Amicus Therapeutics (FOLD) Tops Q3 EPS by 1c

Oct 10, 2023 08:21 AM Amicus Therapeutics (FOLD) PT Lowered to $14 at Morgan Stanley

Oct 2, 2023 08:20 AM Amicus Therapeutics (FOLD) and Blackstone (BX) Enter into $430 Million Strategic Financing Collaboration

Sep 29, 2023 09:03 AM Amicus Therapeutics (FOLD) PT Raised to $20 at UBS

Sep 29, 2023 08:42 AM This biopharma stock's valuation is attractive at current levels says JPMorgan

Sep 29, 2023 07:05 AM Amicus Therapeutics (FOLD) Added to Analyst Focus List at JP Morgan

Sep 29, 2023 07:04 AM Amicus Therapeutics (FOLD) PT Raised to $19 at JPMorgan

Sep 28, 2023 04:04 PM Amicus Therapeutics (FOLD) PT Raised to $18 at Stifel

Sep 28, 2023 10:41 AM Amicus Therapeutics (FOLD) Announces FDA Approval and Launch of Pombiliti + Opfolda

Sep 28, 2023 08:29 AM Amicus Therapeutics (FOLD) Halted, News Pending

Aug 22, 2023 09:17 AM Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" Designated Therapy for Treatment of EB from Amicus Therapeutics (FOLD)

Aug 9, 2023 09:22 AM Amicus Therapeutics (FOLD) PT Raised to $19 at UBS

Aug 8, 2023 07:08 AM Amicus Therapeutics (FOLD) Misses Q2 EPS by 4c

May 10, 2023 07:14 AM Amicus Therapeutics (FOLD) Misses Q1 EPS by 4c

Apr 26, 2023 01:01 PM Amicus Therapeutics (FOLD) Receives Positive CHMP Opinion for Opfolda

Apr 24, 2023 06:21 AM Amicus Therapeutics (FOLD) PT Lowered to $16 at BofA Securities

Mar 28, 2023 09:36 AM Amicus Therapeutics (FOLD) PT Raised to $17 at BofA Securities

Mar 27, 2023 07:03 AM Amicus Therapeutics (FOLD) Announces European Commission Approval for Pombiliti

Mar 20, 2023 12:53 PM Amicus Therapeutics (FOLD) receives European Commission approval of Pombiliti

Mar 10, 2023 01:12 PM Stifel Lays Out Biotech Names Exposure to SVB Financial Group (SIVB)

Mar 2, 2023 07:13 AM Amicus Therapeutics (FOLD) PT Raised to $17 at UBS

Mar 2, 2023 06:00 AM Amicus Therapeutics (FOLD) PT Raised to $11 at Goldman Sachs

Feb 22, 2023 05:00 PM Amicus Therapeutics (FOLD) Reports Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA

Jan 17, 2023 03:39 PM Amicus Therapeutics (FOLD) PT Raised to $16 at BTIG

Jan 17, 2023 08:20 AM Amicus Therapeutics (FOLD) PT Raised to $17 at Stifel

Jan 12, 2023 04:18 PM Jefferies Starts FormFactor (FORM) at Hold (correction)

Jan 9, 2023 07:17 AM Amicus Therapeutics (FOLD) Prelim. FY Revenue Tops Consensus

Dec 16, 2022 08:11 AM Amicus Therapeutics (FOLD) Receives Positive CHMP Opinion for Pombiliti for Late-Onset Pompe Disease

Nov 8, 2022 08:24 AM Amicus Therapeutics (FOLD) PT Lowered to $13 at Stifel

Nov 7, 2022 12:20 PM Amicus Therapeutics (FOLD) Provides EU Regulatory Update for AT-GAA

Nov 1, 2022 05:29 AM Amicus Therapeutics (FOLD) PT Raised to $12 at Berenberg

Oct 28, 2022 04:01 PM Amicus Therapeutics (FOLD) Announces FDA Deferral of Action on Filing for AT-GAA in Late-onset Pompe Disease

Sep 9, 2022 02:42 AM Morgan Stanley Starts Amicus Therapeutics (FOLD) at Equalweight

Aug 4, 2022 07:33 AM Amicus Therapeutics (FOLD) Reports In-Line Q2 EPS

May 10, 2022 04:01 PM Amicus Therapeutics (FOLD) Announces 90-Days PDUFA Date Extensions for AT-GAA

Apr 19, 2022 07:02 AM Amicus Therapeutics (FOLD) Issues New US Composition of Matter Patent for Galafold

Apr 13, 2022 06:37 AM UPDATE: Goldman Sachs Reinstates Amicus Therapeutics (FOLD) at Neutral

Mar 16, 2022 07:01 AM Amicus Therapeutics (FOLD) Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference

Feb 25, 2022 09:07 AM Amicus Therapeutics (FOLD) PT Lowered to $15 at JPMorgan

Feb 25, 2022 08:28 AM Amicus Therapeutics (FOLD) PT Lowered to $20 at Cowen

Feb 25, 2022 06:02 AM Amicus Therapeutics (FOLD) PT Lowered to $15 at BofA Securities

Feb 24, 2022 06:32 PM Amicus Therapeutics (FOLD) PT Lowered to $14 at Stifel

Feb 24, 2022 02:35 PM Amicus Therapeutics (FOLD) PT Lowered to $14 at BTIG